[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615885":3},{"organization":4,"outcomesModule":7,"designInfo":43,"detailedDescription":11,"studyPopulation":11,"armGroups":54,"interventions":65,"overallOfficials":75,"centralContacts":79,"locations":87,"responsibleParty":258,"collaborators":11,"id":260,"slug":261,"hasResults":262,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":262,"sex":268,"minAge":269,"maxAge":270,"enrollmentInfo":271,"targetDuration":11,"studyType":274,"phases":275,"briefSummary":277,"conditions":278,"keywords":11,"overallStatus":90,"whyStopped":11,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":289},{"fullName":5,"class":6},"Hoffmann-La Roche","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":15,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Percentage of Participants With Clinical Remission per Pediatric Crohn's Disease Activity Index (PCDAI)",null,"At Week 52",{"measure":14,"description":11,"timeFrame":12},"Percentage of Participants With Endoscopic Response",[16,19,21,23,26,28,30,32,34,36,38,41],{"measure":17,"description":11,"timeFrame":18},"Percentage of Participants With Clinical Remission","At Week 12 and Week 52",{"measure":20,"description":11,"timeFrame":18},"Percentage of Participants With Clinical Response",{"measure":22,"description":11,"timeFrame":18},"Percentage of Participants With CDAI Remission",{"measure":24,"description":11,"timeFrame":25},"Change From Baseline in Fecal Calprotectin","Baseline, Week 12 and Week 52",{"measure":27,"description":11,"timeFrame":25},"Change From Baseline in Mucosal Inflammation Noninvasive Index (MINI) Score",{"measure":29,"description":11,"timeFrame":12},"Percentage of Participants With Endoscopic Remission",{"measure":31,"description":11,"timeFrame":12},"Percentage of Participants With Corticosteroid-Free Clinical Remission",{"measure":33,"description":11,"timeFrame":18},"Percentage of Participants with Maintenance of Remission",{"measure":35,"description":11,"timeFrame":12},"Percentage of Participants With Histologic Improvement",{"measure":37,"description":11,"timeFrame":12},"Percentage of Participants With Ulcer-Free Endoscopy",{"measure":39,"description":11,"timeFrame":40},"Incidence and Severity of Adverse Events (AEs)","Up to Approximately 5.5 Years",{"measure":42,"description":11,"timeFrame":40},"Serum Concentration of Afimkibart",{"allocation":44,"interventionModel":45,"interventionModelDescription":11,"primaryPurpose":46,"observationalModel":11,"timePerspective":11,"maskingInfo":47},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":48,"maskingDescription":11,"whoMasked":49},"QUADRUPLE",[50,51,52,53],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[55,61],{"label":56,"type":57,"description":58,"interventionNames":59},"Afimkibart Dose A","EXPERIMENTAL","Participants will receive Afimkibart intravenously (IV) followed by Afimkibart subcutaneous (SC) injection.",[60],"Drug: Afimkibart",{"label":62,"type":57,"description":63,"interventionNames":64},"Afimkibart Dose B","Participants will receive Afimkibart IV followed by Afimkibart SC.",[60],[66],{"type":67,"name":68,"description":69,"armGroupLabels":70,"otherNames":71},"DRUG","Afimkibart","Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.",[56,62],[72,73,74],"RO7790121","PF-06480605","RVT-3101",[76],{"name":77,"affiliation":5,"role":78},"Clinical Trials","STUDY_DIRECTOR",[80,85],{"name":81,"role":82,"phone":83,"phoneExt":11,"email":84},"Reference Study ID Number: CP45906 https:\u002F\u002Fforpatients.roche.com\u002F No attachments to email below.","CONTACT","888-662-6728 (U.S. and Canada)","global-roche-genentech-trials@gene.com",{"name":86,"role":82,"phone":11,"phoneExt":11,"email":11},"Fastest response: use the inquiry form. https:\u002F\u002Fwww.gene.com\u002Fcontact-us\u002Fsubmit-medical-inquiry",[88,101,113,123,133,145,155,163,175,184,196,205,216,227,233,238,249],{"facility":89,"status":90,"city":91,"state":91,"zip":92,"country":93,"countryCode":94,"cosmosGeoPoint":95,"geoPoint":100,"contacts":11},"NYU Langone Health","RECRUITING","New York","10016","United States","US",{"type":96,"coordinates":97},"Point",[98,99],-74.00597,40.71427,{"lat":99,"lon":98},{"facility":102,"status":90,"city":103,"state":104,"zip":105,"country":106,"countryCode":107,"cosmosGeoPoint":108,"geoPoint":112,"contacts":11},"Mater Hospital Brisbane","South Brisbane","Queensland","4101","Australia","AU",{"type":96,"coordinates":109},[110,111],153.02049,-27.48034,{"lat":111,"lon":110},{"facility":114,"status":90,"city":115,"state":116,"zip":117,"country":106,"countryCode":107,"cosmosGeoPoint":118,"geoPoint":122,"contacts":11},"Royal Children's Hospital","Parkville","Victoria","3052",{"type":96,"coordinates":119},[120,121],144.95,-37.78333,{"lat":121,"lon":120},{"facility":124,"status":90,"city":125,"state":126,"zip":127,"country":106,"countryCode":107,"cosmosGeoPoint":128,"geoPoint":132,"contacts":11},"Perth Children's Hospital","Nedlands","Western Australia","6009",{"type":96,"coordinates":129},[130,131],115.8073,-31.98184,{"lat":131,"lon":130},{"facility":134,"status":90,"city":135,"state":136,"zip":137,"country":138,"countryCode":139,"cosmosGeoPoint":140,"geoPoint":144,"contacts":11},"Santa Casa de Misericordia de Porto Alegre","Porto Alegre","Rio Grande do Sul","90035-074","Brazil","BR",{"type":96,"coordinates":141},[142,143],-51.23019,-30.03283,{"lat":143,"lon":142},{"facility":146,"status":90,"city":147,"state":148,"zip":149,"country":138,"countryCode":139,"cosmosGeoPoint":150,"geoPoint":154,"contacts":11},"CECIP - Centro de Estudos Clínicos do Interior Paulista","Jaú","São Paulo","17201-130",{"type":96,"coordinates":151},[152,153],-48.55778,-22.29639,{"lat":153,"lon":152},{"facility":156,"status":90,"city":148,"state":148,"zip":157,"country":138,"countryCode":139,"cosmosGeoPoint":158,"geoPoint":162,"contacts":11},"BR Trials - Pesquisa Clínica","01236-030",{"type":96,"coordinates":159},[160,161],-46.63611,-23.5475,{"lat":161,"lon":160},{"facility":164,"status":90,"city":165,"state":166,"zip":167,"country":168,"countryCode":169,"cosmosGeoPoint":170,"geoPoint":174,"contacts":11},"Centro de Investigación Clínica Acelerada, S.C","Mexico City","Mexico CITY (federal District)","07369","Mexico","MX",{"type":96,"coordinates":171},[172,173],-99.12766,19.42847,{"lat":173,"lon":172},{"facility":176,"status":90,"city":177,"state":11,"zip":178,"country":168,"countryCode":169,"cosmosGeoPoint":179,"geoPoint":183,"contacts":11},"FAICIC Clinical Research","Veracruz","91900",{"type":96,"coordinates":180},[181,182],-96.1429,19.18095,{"lat":182,"lon":181},{"facility":185,"status":90,"city":186,"state":187,"zip":188,"country":189,"countryCode":190,"cosmosGeoPoint":191,"geoPoint":195,"contacts":11},"Emmed Research","Pretoria","Gauteng","84","South Africa","ZA",{"type":96,"coordinates":192},[193,194],28.18783,-25.74486,{"lat":194,"lon":193},{"facility":197,"status":90,"city":198,"state":11,"zip":199,"country":189,"countryCode":190,"cosmosGeoPoint":200,"geoPoint":204,"contacts":11},"IATROS International","Bloemfontein","9301",{"type":96,"coordinates":201},[202,203],26.214,-29.12107,{"lat":203,"lon":202},{"facility":206,"status":90,"city":207,"state":11,"zip":208,"country":209,"countryCode":210,"cosmosGeoPoint":211,"geoPoint":215,"contacts":11},"National Taiwan University Hospital","Taipei","100","Taiwan","TW",{"type":96,"coordinates":212},[213,214],121.52639,25.05306,{"lat":214,"lon":213},{"facility":217,"status":90,"city":218,"state":11,"zip":219,"country":220,"countryCode":221,"cosmosGeoPoint":222,"geoPoint":226,"contacts":11},"Chulalongkorn University","Bangkok","10330","Thailand","TH",{"type":96,"coordinates":223},[224,225],100.50144,13.75398,{"lat":225,"lon":224},{"facility":228,"status":90,"city":218,"state":11,"zip":229,"country":220,"countryCode":221,"cosmosGeoPoint":230,"geoPoint":232,"contacts":11},"Siriraj Hospital","10700",{"type":96,"coordinates":231},[224,225],{"lat":225,"lon":224},{"facility":234,"status":90,"city":218,"state":11,"zip":11,"country":220,"countryCode":221,"cosmosGeoPoint":235,"geoPoint":237,"contacts":11},"Ramathibodi Hospital",{"type":96,"coordinates":236},[224,225],{"lat":225,"lon":224},{"facility":239,"status":90,"city":240,"state":11,"zip":241,"country":242,"countryCode":243,"cosmosGeoPoint":244,"geoPoint":248,"contacts":11},"King's College Hospital","London","SE5 9RS","United Kingdom","UK",{"type":96,"coordinates":245},[246,247],-0.12574,51.50853,{"lat":247,"lon":246},{"facility":250,"status":90,"city":251,"state":11,"zip":252,"country":242,"countryCode":243,"cosmosGeoPoint":253,"geoPoint":257,"contacts":11},"Sheffield Childrens Hospital","Sheffield","S10 2TH",{"type":96,"coordinates":254},[255,256],-1.4659,53.38297,{"lat":256,"lon":255},{"type":259,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100615885","a-study-to-assess-the-pharmacokinetics-effectiveness-and-safety-of-afimkibart-for-induction-and-maintenance-therapy-in-children-with-moderately-to-severely-active-crohns-disease-100615885",false,"NCT07298421","A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease","A Phase III Randomized Double-Blind Multi-Center Treat-Through Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Children Aged 2-17 Years With Moderately to Severely Active Crohn's Disease","SIBERITE-PEDS","Inclusion Criteria:\n\n* Body weight \\>= 10 kilogram (kg)\n* Active CD confirmed by endoscopy (ileocolonoscopy)\n* Moderately to severely active CD, defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score \\>= 30, and Simple Endoscopic Score Crohn's Disease (SES-CD) \\>=6 (or \\>=4 for isolated ileal disease) confirmed through centrally-read ileocolonoscopy\n* Inadequate response, loss of response, and\u002For intolerance to at least one of the following conventional therapies (aminosalicylates, corticosteroids and\u002For immunosuppressants) or advanced therapies (including anti-tumor necrosis factor, anti-interleukin, anti-integrin, or Janus Kinase (JAK) inhibitors)\n\nExclusion Criteria:\n\n* Monogenic disorder pertaining to infant onset Inflammatory Bowel Disease (IBD)\n* History of \\>= 3 bowel resections: \\> 2 missing segments of the following five segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum\n* Current diagnosis of ulcerative colitis (UC), abdominal\u002Fintraabdominal\u002Fperianal fistula and\u002For abscess, indeterminant colitis, IBD-unclassified, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, or active diverticular disease.\n* Symptomatic bowel strictures, fulminant colitis, or toxic megacolon\n* Presence of abdominal or perianal abscess\n* Current diagnosis or suspicion of primary sclerosing cholangitis","ALL","2 Years","17 Years",{"count":272,"type":273},100,"ESTIMATED","INTERVENTIONAL",[276],"PHASE3","This phase III, double-blind, multi-center treat-through study will evaluate the efficacy and safety of Afimkibart (also known as RO7790121) in children with moderately to severely active Crohn's Disease (CD).",[279],"Moderately to Severely Active Crohns Disease","2026-10-05",{"date":282,"type":283},"2026-10-06","ACTUAL",{"date":285,"type":283},"2026-08-18",{"date":287,"type":273},"2031-05-30",{"name":5,"class":6},17]